Genprex Seeks Shareholder Approval for Another Reverse Stock Split and Significant Equity Plan Increase Amidst Delisting Risk

summarizeSummary

Genprex is asking shareholders to approve another reverse stock split (1:5 to 1:50) to maintain its Nasdaq listing, despite having completed two recent splits, and a 20% increase in its equity incentive plan, highlighting significant financial and compliance pressures.

check_boxKey Events · Corporate Governance and Compliance · GNPX

• Authorization for Another Reverse Stock Split

  Shareholders are asked to approve an amendment to the company's charter to effect a reverse stock split at a ratio between 1:5 and 1:50, at the Board's discretion, until December 31, 2027. This is primarily aimed at maintaining compliance with Nasdaq's $1.00 minimum bid price requirement.

• History of Reverse Stock Splits and Delisting Risk

  The company previously implemented a 1:40 reverse stock split in February 2024 and a 1:50 reverse stock split in October 2025. The filing highlights that under amended Nasdaq rules, if another reverse split is implemented and the stock price falls below $1.00 within one year, the company will face immediate delisting without a compliance period, indicating a heightened risk.

• Significant Increase in Equity Incentive Plan

  The Board recommends increasing the shares authorized for issuance under the 2018 Equity Incentive Plan by an additional 1,850,000 shares. This represents a potential dilution of approximately 20.1% based on the 9,205,437 shares outstanding as of April 15, 2026.

auto_awesomeAnalysis · GNPX · Life Sciences

Genprex, Inc. is seeking shareholder approval for two critical proposals at its upcoming annual meeting: a reverse stock split and a substantial increase in its equity incentive plan. The proposed reverse stock split, with a ratio ranging from 1:5 to 1:50, is intended to help the company maintain its Nasdaq listing, which requires a minimum bid price of $1.00. This is particularly concerning as the company has already implemented two reverse stock splits (1:40 in February 2024 and 1:50 in October 2025) in a short period. The filing explicitly warns that under amended Nasdaq rules, if another reverse split is implemented and the stock price subsequently falls below $1.00 within a year, the company will face immediate delisting without a compliance period. This indicates a precarious position regarding its listing status. Additionally, the company is requesting to increase the shares authorized for its 2018 Equity Incentive Plan by an additional 1,850,000 shares, representing a potential dilution of over 20% based on current outstanding shares. This significant potential dilution, coupled with the ongoing struggle to maintain Nasdaq compliance, signals considerable financial and operational challenges for the company.